Rodney JY Ho

Rodney JY Ho is a Professor at the University of Washington School of Pharmacy and founding Executive Director of the NIH-designated Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH). He directs the Targeted Long-Acting Combination Antiretroviral Therapy (TLC-ART) Program and holds affiliate appointments at Fred Hutchinson Cancer Research Center, CFAR, and ITHS.

• PhD, University of Tennessee
• Bachelor of Science, University of California
• Post-Doctoral Fellow, Stanford University

His research focuses on bio-nanotechnology and systems pharmacology for targeted drug delivery, long-acting therapeutics, and combination therapies in HIV/AIDS and cancer. Key areas include pharmacokinetics-pharmacodynamics modeling, lipid-drug interactions, and nanomedicine development.

Recent publications highlight his work on long-acting antiretroviral nanoparticles, systems pharmacology for viral therapies, and nanotherapeutic translation spanning 2014–2022. Trends include sustained drug release, lymphatic targeting, and computational pharmacokinetic modeling for pandemic response.

Scientific Recognition:

• Elected Fellow of AAAS and AAPS
• Paul Dawson Biotechnology Lifetime Achievement Award
• Volwiler Lifetime Research Achievement Award
• AAPS Biotechnology Research Achievement Award
• Member of National Academy of Innovators

Rodney Ho leads the TLC-ART program—a collaborative team of scientists, physicians, and students developing targeted therapies for HIV and cancer. His work integrates pharmacokinetic modeling, nanotechnology, and biopharmaceutical translation, supported by NIH grants and international partnerships.